1 week ago
13
Biomedicines, Vol. 12, Pages 2605: Osteopontin and Clinical Outcomes in Hemodialysis Patients
Biomedicines doi: 10.3390/biomedicines12112605
Authors: Claudia Torino Federico Carbone Patrizia Pizzini Sabrina Mezzatesta Graziella D’Arrigo Mercedes Gori Luca Liberale Margherita Moriero Cristina Michelauz Federica Frè Simone Isoppo Aurora Gavoci Federica La Rosa Alessandro Scuricini Amedeo Tirandi Davide Ramoni Francesca Mallamaci Giovanni Tripepi Fabrizio Montecucco Carmine Zoccali
Background/Objectives: Chronic kidney disease (CKD) and end-stage kidney disease (ESKD) are significant public health issues, with cardiovascular morbidity and mortality being the leading causes of death in hemodialysis patients. Osteopontin (OPN), a multifunctional glycoprotein, has emerged as a potential biomarker for vascular disease in CKD due to its role in inflammation, tissue remodeling, and calcification. Methods: This cohort study included 1124 hemodialysis patients from the PROGREDIRE study, a registry involving 35 dialysis units in Southern Italy. Serum osteopontin levels were measured using enzyme-linked immunosorbent assay (ELISA). The primary endpoints were all-cause and cardiovascular mortality. Multivariate Cox regression analyses were performed to assess the association between osteopontin levels and mortality, adjusting for traditional risk factors, biomarkers of inflammation, nutritional status, and ESKD-related factors. Results: During a mean follow-up of 2.8 years, 478 patients died, 271 from cardiovascular causes. Independent correlates of osteopontin included alkaline phosphatase and parathyroid hormone. Elevated osteopontin levels were significantly associated with increased all-cause mortality (HR 1.19, 95% CI 1.09–1.31, p < 0.001) and cardiovascular mortality (HR 1.22, 95% CI 1.08–1.38, p = 0.001) after adjusting for confounders. Conclusions: Elevated osteopontin levels are associated with increased all-cause and cardiovascular mortality in hemodialysis patients. These findings implicate osteopontin in the high risk for death and cardiovascular disease in the hemodialysis population. Intervention studies are needed to definitively test this hypothesis.
